Syros Pharmaceuticals, Inc.

SYRS · NASDAQ
Analyze with AI
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Assets
Cash & Equivalents$139,526$167,467$92,302$173,984
Short-Term Investments$0$34,837$38,067$0
Receivables$0$1,694$2,979$2,331
Inventory$0$0$0$0
Other Curr. Assets$5,454$7,394$3,237$2,242
Total Curr. Assets$144,980$211,392$136,585$178,557
Property Plant & Equip (Net)$19,483$24,660$27,285$29,641
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$2,119$3,086$13,038$3,086
Tax Assets$0$0$0$0
Other NC Assets$1,592$5,348$6,027$1,966
Total NC Assets$23,194$33,094$46,350$34,693
Other Assets$0$0$0$0
Total Assets$168,174$244,486$182,935$213,250
Liabilities
Payables$11,544$6,411$3,692$3,603
Short-Term Debt$8,991$2,071$2,011$3,456
Tax Payable$0$0$0$0
Deferred Revenue$0$4,330$10,181$12,209
Other Curr. Liab.$16,146$17,966$15,624$9,356
Total Curr. Liab.$36,681$30,778$31,508$28,624
LT Debt$53,084$61,500$63,180$64,485
Deferred Rev, NC$0$0$0$9,877
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$61,747$24,472$3,029$19,711
Total NC Liab.$114,831$85,972$66,209$94,073
Other Liabilities$0$0$0$0
Cap. Leases$20,852$22,922$24,934$26,662
Total Liabilities$151,512$116,750$97,717$122,697
Equity
Pref Stock$0$0$0$0
Common Stock$26$20$61$56
Retained Earnings-$722,807-$558,233-$463,579-$377,021
AOCI$0$102-$79$0
Other Equity$739,443$685,847$548,815$467,518
Total Equity$16,662$127,736$85,218$90,553
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$168,174$244,486$182,935$213,250
Net Debt-$77,451-$103,896-$27,111-$106,043